Kati Erdmann1, Knut Kaulke2, Christiane Rieger2, Manfred P Wirth2, Susanne Fuessel2. 1. Department of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. kati.erdmann@uniklinikum-dresden.de. 2. Department of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Abstract
PURPOSE: Alpha-methylacyl-CoA racemase (AMACR) is highly overexpressed in prostate cancer (PCa) and its transcriptional regulators include various transcription factors and CTNNB1/β-catenin. Our previous findings suggested a post-transcriptional regulation by the tumor-suppressive microRNA miR-138 in PCa. Thus, the aim of this study was to demonstrate the direct interaction of miR-138 with the 3'-UTR of AMACR. Furthermore, the influence of miR-138 on the expression of AMACR and selected AMACR regulators was investigated in PCa cells. METHODS: Using DU-145, PC-3, and LNCaP PCa cells, the effect of exogenous miR-138 on AMACR and selected AMACR regulators was determined by quantitative PCR and Western blot. Luciferase reporter assays were used to verify target and promoter interaction. RESULTS: Using a luciferase reporter assay a direct interaction of miR-138 with the AMACR-3'-UTR was confirmed. Surprisingly, AMACR expression was up-regulated by up to 125% by exogenous miR-138 in PCa cells. The lack of any miR-138 binding sites within the AMACR promoter suggested an indirect mechanism of up-regulation. Therefore, the effect of miR-138 on selected AMACR regulators including CTNNB1/β-catenin, RELA, SMAD4, SP1, and TCF4 was evaluated. MiR-138 solely evoked an up-regulation of CTNNB1 mRNA expression and β-catenin protein levels by up to 75%. Further in silico analysis revealed a binding site for miR-138 within the CTNNB1 promoter. MiR-138 could enhance the activity of the CTNNB1 promoter, which in turn could contribute to the observed AMACR up-regulation. CONCLUSIONS: The present findings suggest that miR-138 can indirectly up-regulate AMACR via transcriptional induction of CTNNB1, at least in vitro in PCa cells.
PURPOSE:Alpha-methylacyl-CoA racemase (AMACR) is highly overexpressed in prostate cancer (PCa) and its transcriptional regulators include various transcription factors and CTNNB1/β-catenin. Our previous findings suggested a post-transcriptional regulation by the tumor-suppressive microRNA miR-138 in PCa. Thus, the aim of this study was to demonstrate the direct interaction of miR-138 with the 3'-UTR of AMACR. Furthermore, the influence of miR-138 on the expression of AMACR and selected AMACR regulators was investigated in PCa cells. METHODS: Using DU-145, PC-3, and LNCaP PCa cells, the effect of exogenous miR-138 on AMACR and selected AMACR regulators was determined by quantitative PCR and Western blot. Luciferase reporter assays were used to verify target and promoter interaction. RESULTS: Using a luciferase reporter assay a direct interaction of miR-138 with the AMACR-3'-UTR was confirmed. Surprisingly, AMACR expression was up-regulated by up to 125% by exogenous miR-138 in PCa cells. The lack of any miR-138 binding sites within the AMACR promoter suggested an indirect mechanism of up-regulation. Therefore, the effect of miR-138 on selected AMACR regulators including CTNNB1/β-catenin, RELA, SMAD4, SP1, and TCF4 was evaluated. MiR-138 solely evoked an up-regulation of CTNNB1 mRNA expression and β-catenin protein levels by up to 75%. Further in silico analysis revealed a binding site for miR-138 within the CTNNB1 promoter. MiR-138 could enhance the activity of the CTNNB1 promoter, which in turn could contribute to the observed AMACR up-regulation. CONCLUSIONS: The present findings suggest that miR-138 can indirectly up-regulate AMACR via transcriptional induction of CTNNB1, at least in vitro in PCa cells.
Authors: J L Requenez-Contreras; E S López-Castillejos; R Hernández-Flores; M A Moreno-Eutimio; J T Granados-Riveron; G U Martinez-Ruiz; G Aquino-Jarquin Journal: Biochem Biophys Res Commun Date: 2017-01-31 Impact factor: 3.575
Authors: Tanner J Freeman; J Joshua Smith; Xi Chen; M Kay Washington; Joseph T Roland; Anna L Means; Steven A Eschrich; Timothy J Yeatman; Natasha G Deane; R Daniel Beauchamp Journal: Gastroenterology Date: 2011-11-22 Impact factor: 22.682
Authors: Sandrine Sander; Lars Bullinger; Kay Klapproth; Katja Fiedler; Hans A Kestler; Thomas F E Barth; Peter Möller; Stephan Stilgenbauer; Jonathan R Pollack; Thomas Wirth Journal: Blood Date: 2008-08-19 Impact factor: 22.113
Authors: Shan Zha; Sacha Ferdinandusse; Simone Denis; Ronald J Wanders; Charles M Ewing; Jun Luo; Angelo M De Marzo; William B Isaacs Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: Steven W Paugh; David R Coss; Ju Bao; Lucas T Laudermilk; Christy R Grace; Antonio M Ferreira; M Brett Waddell; Granger Ridout; Deanna Naeve; Michael Leuze; Philip F LoCascio; John C Panetta; Mark R Wilkinson; Ching-Hon Pui; Clayton W Naeve; Edward C Uberbacher; Erik J Bonten; William E Evans Journal: PLoS Comput Biol Date: 2016-02-04 Impact factor: 4.475
Authors: Anthony Mathelier; Oriol Fornes; David J Arenillas; Chih-Yu Chen; Grégoire Denay; Jessica Lee; Wenqiang Shi; Casper Shyr; Ge Tan; Rebecca Worsley-Hunt; Allen W Zhang; François Parcy; Boris Lenhard; Albin Sandelin; Wyeth W Wasserman Journal: Nucleic Acids Res Date: 2015-11-03 Impact factor: 16.971